| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 10/17/2001 | EP1144459A2 Cross-linked hyaluronic acids and medical uses thereof |
| 10/17/2001 | EP1144458A1 Substance for reduction of cholesterol as well as lipids content |
| 10/17/2001 | EP1144420A1 Sulfated phosphatidylinositols, their preparation and use |
| 10/17/2001 | EP1144377A1 Oxetanone derivatives |
| 10/17/2001 | EP1144323A2 Biodegradable ceramic fibres from silica sols |
| 10/17/2001 | EP1144065A1 Apparatus and process for preparing crystalline particles |
| 10/17/2001 | EP1144015A1 Treating protein-containing liquids |
| 10/17/2001 | EP1144013A1 Lactone bearing absorbable polymers |
| 10/17/2001 | EP1144009A2 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
| 10/17/2001 | EP1144003A1 Methods and devices for delivery of agents to breast milk ducts |
| 10/17/2001 | EP1143995A1 Anti-dandruff composition comprising an antifungal polypeptide |
| 10/17/2001 | EP1143992A2 Therapeutic compositions containing glutathione analogs |
| 10/17/2001 | EP1143985A2 Use of lactobacillus salivarius |
| 10/17/2001 | EP1143983A1 Spray delivery of cells |
| 10/17/2001 | EP1143982A2 Method for preparing membrane vesicles |
| 10/17/2001 | EP1143978A2 Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding |
| 10/17/2001 | EP1143973A2 Compositions having improved stability |
| 10/17/2001 | EP1143963A1 Multiparticulate bisoprolol formulation |
| 10/17/2001 | EP1143962A1 Parenteral solution of propofol (2,6-diisoprophylphenol) and 2.5-di-0-methyl-1.4;3.6-dianhydro-d-glucitol as a solvent |
| 10/17/2001 | EP1143956A2 Compositions and methods for the treatment of anorectal disorders |
| 10/17/2001 | EP1143954A2 Use of nicotonic acid derivatives for the treatment of dna damage in skin cells |
| 10/17/2001 | EP1143947A2 Use of estrogen compounds for prevention and treatment of ischemic damage |
| 10/17/2001 | EP1143940A2 Compositions and methods for mucosal delivery |
| 10/17/2001 | EP1143939A2 Therapeutic system containing an active substance for the application on the skin which contains at least two polymerous layers |
| 10/17/2001 | EP1143938A2 Phinan |
| 10/17/2001 | EP1143937A2 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| 10/17/2001 | EP1143936A2 MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN $g(a)-ANTAGONIST |
| 10/17/2001 | EP1143935A2 Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 10/17/2001 | EP1143934A1 Genetic immunization with co-delivery of nucleic acid and cytokines |
| 10/17/2001 | EP1143933A2 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
| 10/17/2001 | EP1143932A1 Transnasal transport/immunisation with highly adaptable carriers |
| 10/17/2001 | EP1143931A1 Pulmonary drug delivery |
| 10/17/2001 | EP1143930A2 Pharmaceutical formulation of fluticasone propionate |
| 10/17/2001 | EP1143929A1 BIODEGRADABLE pH/THERMOSENSITIVE HYDROGELS FOR SUSTAINED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS |
| 10/17/2001 | EP1143928A1 Milling process for the production of finely milled medicinal substances |
| 10/17/2001 | EP1143927A2 Facial tissue composition and method of use for sequestration of nasal secretion skin irritants |
| 10/17/2001 | EP1143925A1 Topical composition comprising n-acetylaldosamines or n-acetylamino acids |
| 10/17/2001 | EP1143920A1 Oil-in-water emulsion comprising a micronised biologically active agent and an appropriate emulsifier system |
| 10/17/2001 | EP1143910A1 Method and device for producing different solid dosage forms |
| 10/17/2001 | EP1143896A1 Methods of hydrating mucosal surfaces |
| 10/17/2001 | EP1143806A2 Method for increasing pet activity |
| 10/17/2001 | EP1143796A1 Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method |
| 10/17/2001 | EP1007097B1 Formulation of stabilised cationic transfection agent(s)/nucleic acid particles |
| 10/17/2001 | EP0999841B1 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine |
| 10/17/2001 | EP0941063B1 Transdermal compositions containing levosimendan |
| 10/17/2001 | EP0873110A4 Improved hemostatic composition for treating gingival area |
| 10/17/2001 | EP0841930B1 Stable solid formulation of enalapril salt and process for preparation thereof |
| 10/17/2001 | EP0804165B1 Solid medicament form with active agent distributed in polymer material |
| 10/17/2001 | EP0769965B1 Aqueous risperidone formulations |
| 10/17/2001 | EP0759744B1 Narcotic containing aerosol formulation |
| 10/17/2001 | EP0754682B1 Aminostilbazole derivative and medicine |
| 10/17/2001 | EP0751766B1 Nasal and ocular administration of ketamine to manage pain and for detoxification |
| 10/17/2001 | EP0717988B1 Gastric remaining preparation, swollen molding, and production process |
| 10/17/2001 | EP0664696B2 Sustained release compositions for treating periodontal disease |
| 10/17/2001 | EP0554434B1 Imaging of infections |
| 10/17/2001 | CN2453894Y Alihong-powder sponge turunda |
| 10/17/2001 | CN1318073A Process for obtaining polymers derived from vinyl acetate, and uses thereof |
| 10/17/2001 | CN1318056A Pyridinum derivatives for management of aging-related and diabetic vascular complications, process for their prepn. and therepeutic uses thereof |
| 10/17/2001 | CN1317977A Dry powder active agent pulmonary delivery |
| 10/17/2001 | CN1317973A Prepns. for immunotherapy for cancer having bacterial somatic constituent as active ingredient |
| 10/17/2001 | CN1317971A Antiviral combination comprising lamivudine and abacavir |
| 10/17/2001 | CN1317967A Protein formulations |
| 10/17/2001 | CN1317959A Multiple unit controlled non-independent release pharmaceutical preparations and method for preparing same |
| 10/17/2001 | CN1317958A Microparticle formulation for inhalation |
| 10/17/2001 | CN1317342A Eye preparation |
| 10/17/2001 | CN1317334A Ointment for treating myopia and its preparing process |
| 10/17/2001 | CN1317317A 'Lifeiqing' capsule for treating pulmonary tuberculosis |
| 10/17/2001 | CN1317314A Kelamycin injection and its preparing process |
| 10/17/2001 | CN1317310A Method of preparing solid state creatine dosage and creatine dosage by same |
| 10/17/2001 | CN1317309A Instant oral medincinal preparation |
| 10/17/2001 | CN1073119C Method and compsns. for dry powder formulation of interferons |
| 10/17/2001 | CN1073116C Metal-bonding cystein-free peptides, process for producing them and its pharmaceutical preparation |
| 10/17/2001 | CN1072966C Prepn. of hollow microcapsules |
| 10/17/2001 | CN1072965C Local medicinal compsns. with increasing function of passing skin |
| 10/17/2001 | CN1072964C Colon-specific drug release system |
| 10/17/2001 | CN1072958C Pancreas-recovering thirst-relieving and blood sugar reducing powder, and preparing method thereof |
| 10/17/2001 | CN1072954C Liquid medicine for giving up smoking and its preparing process |
| 10/17/2001 | CN1072949C Medicine for treating anorexia |
| 10/17/2001 | CN1072948C Process for preparing Chinese medicine 'Buxueyimu' particles |
| 10/17/2001 | CN1072944C Externally used Chinese medicine liquid prepared from plants, method and use thereof |
| 10/17/2001 | CN1072937C Oral liquid for giving up drug |
| 10/17/2001 | CN1072934C Pharmaceutical emulsion |
| 10/17/2001 | CN1072933C Albendazole suspension for expelling and controlling parasite in livestock, and prepn. process thereof |
| 10/17/2001 | CN1072929C Transdermal system for simultaneous delivery of a number of active principles |
| 10/16/2001 | USRE37410 Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| 10/16/2001 | US6303697 Fabrication of biocompatible polymeric composites |
| 10/16/2001 | US6303662 Microemulsion |
| 10/16/2001 | US6303647 Plantago majorand piper methysticum compound for use in treating a tobacco or nicotine habit |
| 10/16/2001 | US6303640 Administering oxazole or thiazole derivative compound for reducing side effects of diabetic therapy |
| 10/16/2001 | US6303634 Therapy and prophylaxis of breast cancer in a human by administering to human benzothiophene derivative |
| 10/16/2001 | US6303631 Water-soluble eye drop |
| 10/16/2001 | US6303626 Pharmaceutical formulations in dry form for the oral administration of a cyclic quaternary ammonium compound |
| 10/16/2001 | US6303607 Administering sustained release pharmaceutical dosage form including ranolazine, ph-dependent and ph-independent binders to human suffering from variant or excercise-induced angina |
| 10/16/2001 | US6303588 Applying to portions of the skin of such patient which have abnormal skin cell metabolism bioactive agent comprising adenosine-5-triphosphate, quanosine-5-triphosphate and phosphinositedes and biologically acceptable carrier |
| 10/16/2001 | US6303585 Cross-linked polysaccharide drug carrier |
| 10/16/2001 | US6303582 Compositions and methods for nucleic acid delivery to the lung |
| 10/16/2001 | US6303379 Transfected cells for use in treatment of genetic disorder |
| 10/16/2001 | US6303374 By hybridization with nucleic acid; controlling apoptosis and programmed cell death; alzheimer*s, parkinson*s, autoimmune, and viral diseases; cancer; amyotrophic lateral sclerosis |
| 10/16/2001 | US6303347 Vaccines |
| 10/16/2001 | US6303167 Mixing silica and liquid mixed tocopherol to produce dry free-flowing powders |